1 results
10/Sep/2018
DOI: 10.1590/S1679-45082018RW4175
ABSTRACT The manufacturing process for biological products is complex, expensive and critical to the final product, with an impact on their efficacy and safety. They have been increasingly used to treat several diseases, and account for approximately 50% of the yearly budget for the Brazilian public health system. As the patents of biological products expire, several biosimilars are developed. However, there are concerns regarding their efficacy and safety; therefore, the regulatory agencies establish rules to approve and monitor these products. […]
Keywords: Biosimilar pharmaceuticals; Health Services Accessibility; Public-private sector partnerships